{"schema_version":"secwatch.filing_event.v1","accession":"0001193805-24-000392","form_type":"8-K","ticker":"ARCT","cik":"0001768224","company_name":"Arcturus Therapeutics Holdings Inc.","filed_at":"2024-03-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.457098+00:00","generated_at":"2026-06-04T13:36:33.174558+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Arcturus partner Meiji reports Phase III success for bivalent COVID-19 booster in Japan","bullets":["Bivalent ARCT-2301 (Kostaive) met primary endpoint of non-inferiority vs COMIRNATY bivalent in GMT ratio and SRR difference.","Superiority against Omicron BA.4/5 and Wuhan strain also confirmed in the phase III study in healthy Japanese adults.","No causally-related severe or serious adverse events reported; safety profile supports platform.","Study conducted by Meiji under distribution agreement with CSL Seqirus for Japan market."],"urls":{"canonical":"https://secwatch.observer/filing/0001193805-24-000392","json":"https://secwatch.observer/filing/0001193805-24-000392.json","markdown":"https://secwatch.observer/filing/0001193805-24-000392.md","text":"https://secwatch.observer/filing/0001193805-24-000392.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1768224/000119380524000392/0001193805-24-000392-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1768224/000119380524000392/e619378_8k-arct.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T13:36:33.174558+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}